Trial Profile
The efficiency and safety of rapid acting insulin, glulisine, in the diabetic patients treated with intensive insulin therapy
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Sep 2013
Price :
$35
*
At a glance
- Drugs Insulin glulisine (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms BANDRA
- 30 Aug 2012 New trial record